Clinical Trials > Chemotherapy
It is not the intention of the Cholangiocarcinoma Foundation to provide specific medical advice. We provide website users with information to help them better understand their health conditions and the current approaches related to prevention, diagnosis, treatment and supportive care. You are urged to always seek the advice of your physician or other qualified healthcare provider.
Patients with intrahepatic cholangiocarcinoma who enroll in this study will receive either Melphalan with the investigational Hepatic Delivery System (called Melphalan/HDS) or Cisplatin and Gemcitabine alone, which is standard of care. Patients who enroll will receive gem/cis followed by melphalan, compared to gem/cis.Read More
This is a study for patients with advanced cholangiocarcinoma or gallbladder cancer. It includes chemotherapy (gemcitabine and cisplatin) with the addition of a PI3K inhibitor to try to improve outcome for this group of patientsRead More